Edition:
United States

Redhill Biopharma Ltd (RDHL.OQ)

RDHL.OQ on NASDAQ Stock Exchange Capital Market

11.20USD
2 Dec 2016
Change (% chg)

-- (--)
Prev Close
$11.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
9,965
52-wk High
$16.36
52-wk Low
$8.10

RDHL.OQ

Chart for RDHL.OQ

About

RedHill Biopharma Ltd. is a biopharmaceutical company focused on the development and acquisition of late clinical-stage, orally administered drugs for the treatment of inflammatory and gastrointestinal diseases, and cancer. The Company's products pipeline includes RHB-105, RHB-104, BEKINDA, RHB-106, YELIVA (ABC294640), MESUPRON,... (more)

Overall

No Ratios Available.

Financials

  RDHL.OQ Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -- -- --
ROI: -- -1.09 14.95
ROE: -- -2.39 16.29

BRIEF-Redhill Biopharma reports qtrly loss per ordinary share $0.07

* Redhill biopharma reports 2016 third quarter financial results Source text for Eikon: Further company coverage:

Nov 14 2016

BRIEF-Redhill Biopharma reports positive FDA type B meeting on RHB-105

* Redhill biopharma ltd says confirmatory phase iii study with rhb-105 for h. Pylori infection is planned to be initiated in h1/2017

Nov 10 2016

BRIEF-RedHill Biopharma provides update on ongoing phase III, phase II studies with Bekinda

* RedHill Biopharma Ltd - top-line results from both studies are expected in mid-2017

Nov 03 2016

BRIEF-Redhill Biopharma announces proposed public offering of its American Depository Shares

* Redhill Biopharma Ltd says intends to use proceeds from offering to fund clinical development programs

Nov 01 2016

BRIEF-Redhill Biopharma to allow multiple sclerosis patent in Japan

* Redhill Biopharma announces allowance of a patent in Japan supporting RHB-104 for multiple sclerosis

Oct 18 2016

BRIEF-Redhill Biopharma provides progress update on RHB-104 Phase III crohn's disease program

* Redhill Biopharma provides progress update on RHB104 Phase III crohn's disease program and introduces option for early stop for success in Q2/2017

Oct 06 2016

BRIEF-Redhill Biopharma Ltd and IntelGenx announce RIZAPORT commercialization with pharmatronic co.

* Redhill Biopharma and IntelGenx announce RIZAPORT commercialization term sheet with Pharmatronic Co. for Korea

Sep 21 2016

BRIEF-Redhill Biopharma announces collaboration with Stanford University for YELIVA

* Says collaboration with Stanford University School Of Medicine for evaluation of Redhill's Phase II stage drug, YELIVA

Sep 12 2016

BRIEF-Redhill Biopharma announces approval of European patent

* Redhill Biopharma announces approval of a European patent supporting RHB-104 for multiple sclerosis

Aug 29 2016

BRIEF-Redhill Biopharma provides 2016 semi-annual research and development update

* Estimated timing for top-line results for Phase II study with Bekinda for IBS-D are anticipated in mid-2017 Source text for Eikon: Further company coverage:

Aug 11 2016

Earnings vs. Estimates